NCT01264497View on ClinicalTrials.gov

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions

Type 2 Diabetes

Interventions

DRUG

TH9507

1 and 2 mg, sc daily for 12 weeks

Sponsors

Lead Sponsor

Theratechnologies

All Listed Sponsors

lead

Theratechnologies

INDUSTRY